Last reviewed 2026-04-20 · How we verify

Tamoxifen 60 mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Alopecia
• Nausea
• Diarrhoea
• Anaemia
• Asthenia
• Arthralgia
• Headache
• Neutropenia
• ANAEMIA
• Fatigue
• Stomatitis
• NEUTROPHIL COUNT DECREASED

Key clinical trials

• Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
• New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia (PHASE2)
• A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
• Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer (PHASE2)
• A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (PHASE3)
• De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial (PHASE3)
• Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)
• Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tamoxifen 60 mg CI brief — competitive landscape report
• Tamoxifen 60 mg updates RSS · CI watch RSS
• Pfizer portfolio CI